Dr Peter Surman- Chief Scientific Officer, Douglas CDMO
Many project managers initially lean toward tablets because they appear cost-effective. What are some of the long-term advantages that softgels can provide to drug sponsors compared with tablets or hard capsules?
Tablets can appear to be the most economical dosage form for investigational medicines, and it is natural to want to contain costs as much as possible in the early stages of development. However, softgels offer significant long-term advantages that can lead to a better return on investment for drug sponsors. The primary long-term benefits include improved bioavailability, enhanced patient compliance, and superior product stability. By improving the absorption of a drug, softgels can potentially reduce the required dose, which lowers the cost of the active pharmaceutical ingredient over the product’s lifetime. The unique properties of an oil-filled capsule also mean better protection for the drug from air, leading to a long shelf life and fewer issues with degradation of the active ingredients. When working with highly potent active substances, the softgel platform is more readily contained compared to powder-based tablets and capsules. Ultimately, these factors can reduce costs associated with keeping your product ahead in the marketplace over the long run.
How do softgels help address the challenges of APIs with poor solubility or bioavailability, and what impact can this have on required dosing and therapeutic efficacy?
Softgels are exceptionally effective at addressing the challenges posed by APIs with poor solubility or bioavailability. This is achieved by formulating the API as a solution, suspension, or emulsion within a liquid or semi-solid fill, which is then encapsulated. Encapsulation of the active pharmaceutical ingredient (API) in lipid-based vehicles or self-emulsifying drug delivery systems (SEDDS/SMEDDS) significantly increases solubility in the gastrointestinal tract. The pre-dissolved form of the API ensures rapid dissolution compared to crystalline or solid dosage formats. Enhanced dissolution translates into improved concentration gradients across intestinal membranes, driving higher absorption. Dr Peter Surman, Chief ScientificOfficere Douglas CDMO
Softgels can incorporate various excipients, such as oils and surfactants, that enhance the absorption of lipophilic drugs. These excipients can keep the drug in a solubilized form, making it more readily available for absorption by the body. This is a crucial advantage for many new chemical entities coming out of R&D pipelines.
By increasing bioavailability, softgels can reduce the amount of API needed per dose to achieve the desired therapeutic effect. This not only lowers the cost per dose but can also minimize dose-related side effects, leading to a safer and more effective treatment.
What role does the gelatin shell play in protecting sensitive compounds, and how does this contribute to product stability and shelf life?
The gelatin shell is a critical component that provides a hermetic seal, acting as a powerful protective barrier for the encapsulated fill material. For drug substances that are degraded by light, opacifying ingredients can be added for further protection.
A gelatin capsule is also great for patients to take, as it masks the taste of bitter medicines and is easy to swallow even without water.
Softgels are known for their formulation versatility. Could you explain how this format benefits complex projects such as low-dose drugs, highly potent APIs, or combination therapies?
For low-dose APIs, a homogenous blend is crucial to ensure each capsule contains the same amount of drug. Liquid or semi-solid fills, where the active is dissolved, permit particularly uniform dispersion of the API and avoid the potential for dose segregation that can occur in powder-based formulations like tablets or hard capsules.
For highly potent APIs, the liquid encapsulation process minimizes dust and airborne particles, which is a major safety concern when handling HPAPIs. This reduces the risk of cross-contamination and ensures the safety of manufacturing personnel.
Softgels can encapsulate multiple APIs within a single dosage form, even if the compounds have different physical or chemical properties. This allows for the creation of fixed-dose combination products, simplifying the patient’s medication regimen and potentially improving adherence.
From a manufacturing standpoint, what safety advantages do softgels provide when handling highly potent or hazardous compounds?
Softgels offer significant safety advantages when handling highly potent or hazardous compounds. The primary benefit lies in the closed-system encapsulation process and lack of dust potential once the active ingredient is dissolved or dispersed in a liquid carrier. This significantly reduces the generation of airborne dust particles that are common with tablet compression or powder filling processes. This is especially critical for occupational health and safety, as it minimizes the risk of inhalation or skin exposure for manufacturing staff.
Once the softgel is sealed, the compound is securely contained within the shell, eliminating the risk of spillage or contamination during downstream processing, handling, and packaging.
Patient compliance is a major concern in drug development. How do softgels enhance the patient experience compared with other oral dosage forms?
Patients generally will always choose a softgel over a tablet. Softgels are well-regarded for their ability to enhance the patient experience, which directly improves medication compliance.
They have a smooth, lubricated surface and a flexible shape, making them easier to swallow than hard capsules or large, chalky tablets. This is particularly beneficial for pediatric and geriatric populations or patients with dysphagia (difficulty swallowing).
The sealed gelatin shell effectively masks unpleasant tastes or odors of the encapsulated APIs, making the medication more palatable APR_SeptOct2025.indb 53 and less likely to cause patient aversion. This is a common issue with many APIs.
Softgels can be manufactured in various colors, shapes, and sizes, which can help patients easily differentiate between different medications, reducing the risk of accidental mix-ups.
Finally, in terms of market strategy, how do softgels provide drug sponsors with a competitive edge in preventing generic competition or copycat formulations?
Softgels provide a competitive edge for drug sponsors, especially in preventing generic competition.
The formulation inside a softgel is often a complex liquid matrix or suspension, which is challenging for generic manufacturers to reverse-engineer compared to a simple powder-based tablet. This complexity acts as a formulation patent barrier, making it difficult for competitors to replicate the product and its bioavailability profile without significant R&D investment.
Softgel products need to be made by skilled operators on dedicated equipment, and even in instances of generic competition, there are typically fewer competitors for softgels than tablets or hardgel capsules of similar commercial potential.
The unique appearance, improved patient experience, and potential for higher bioavailability make the softgel product stand out in the market. This creates a strong brand identity and consumer preference, which can protect market share with know-how beyond patent expiration.
Your asset is not just a medicine; it is a medicine delivered better.
Subscribe to our e-Newsletters.
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!